Fidaxomicin: Difference between revisions
No edit summary |
|||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''Fidaxomicin''' (trade names '''Dificid''', '''Dificlir''', and previously OPT-80 and PAR-101) is the first in a new class of narrow spectrum [[Macrocycle|macrocyclic]] [[antibiotic]] drugs.<ref>{{cite journal |doi=10.1358/dof.2006.031.06.1000709 |title=Tiacumicin B |year=2006 |last1=Revill |first1=P. |last2=Serradell |first2=N. |last3=Bolós |first3=J. |journal=Drugs of the Future |volume=31 |issue=6 |pages=494}}</ref> It is a fermentation product obtained from the actinomycete ''[[Dactylosporangium]] aurantiacum subspecies hamdenesis''.<ref name=PrescribingInfo>{{cite web |publisher=Optimer Pharmaceuticals |url=http://www.dificid.com/upload/dificid.pdf |title=Dificid, Full Prescribing Information |year=2013}}</ref><ref>{{cite journal |doi=10.2165/11537730-000000000-00000 |title=Fidaxomicin |year=2012 |journal=Drugs in R&D |volume=10 |pages=37}}</ref> | |||
Fidaxomicin is non-systemic, meaning it is minimally absorbed into the bloodstream, it is [[bactericidal]], and it has demonstrated selective eradication of [[pathogenic]] ''[[Clostridium difficile]]'' with minimal disruption to the multiple species of [[bacteria]] that make up the normal, healthy [[intestinal flora]]. The maintenance of normal physiological conditions in the colon can reduce the probability of ''Clostridium difficile'' infection recurrence.<ref>{{cite journal |doi=10.1128/AAC.01443-07 |title=OPT-80 Eliminates Clostridium difficile and is Sparing of Bacteroides Species during Treatment of C. Difficile Infection |year=2008 |last1=Louie |first1=T. J. |last2=Emery |first2=J. |last3=Krulicki |first3=W. |last4=Byrne |first4=B. |last5=Mah |first5=M. |journal=Antimicrobial Agents and Chemotherapy |volume=53 |pages=261–3 |pmid=18955523 |issue=1 |pmc=2612159}}</ref> | |||
<ref>{{cite journal |doi=10.1016/j.jinf.2009.03.010 |title=Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes |year=2009 |last1=Johnson |first1=Stuart |journal=Journal of Infection |volume=58 |issue=6 |pages=403–10 |pmid=19394704}}</ref> | |||
It is marketed by Cubist Pharmaceuticals after acquisition of its the originating company Optimer Pharmaceuticals. The target use is for treatment of ''Clostridium difficile'' infection. | |||
Fidaxomicin is available in a 200 mg tablet that is administered every 12 hours for a recommended duration of 10 days. Total duration of therapy should be determined by the patient's clinical status. | |||
==Category== | ==Category== | ||
Revision as of 03:40, 9 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Fidaxomicin (trade names Dificid, Dificlir, and previously OPT-80 and PAR-101) is the first in a new class of narrow spectrum macrocyclic antibiotic drugs.[1] It is a fermentation product obtained from the actinomycete Dactylosporangium aurantiacum subspecies hamdenesis.[2][3] Fidaxomicin is non-systemic, meaning it is minimally absorbed into the bloodstream, it is bactericidal, and it has demonstrated selective eradication of pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora. The maintenance of normal physiological conditions in the colon can reduce the probability of Clostridium difficile infection recurrence.[4] [5]
It is marketed by Cubist Pharmaceuticals after acquisition of its the originating company Optimer Pharmaceuticals. The target use is for treatment of Clostridium difficile infection. Fidaxomicin is available in a 200 mg tablet that is administered every 12 hours for a recommended duration of 10 days. Total duration of therapy should be determined by the patient's clinical status.
Category
US Brand Names
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Overdosage | Clinical Studies | Dosage and Administration | How Supplied | Labels and Packages
Mechanism of Action
References
- ↑ Revill, P.; Serradell, N.; Bolós, J. (2006). "Tiacumicin B". Drugs of the Future. 31 (6): 494. doi:10.1358/dof.2006.031.06.1000709.
- ↑ "Dificid, Full Prescribing Information" (PDF). Optimer Pharmaceuticals. 2013.
- ↑ "Fidaxomicin". Drugs in R&D. 10: 37. 2012. doi:10.2165/11537730-000000000-00000.
- ↑ Louie, T. J.; Emery, J.; Krulicki, W.; Byrne, B.; Mah, M. (2008). "OPT-80 Eliminates Clostridium difficile and is Sparing of Bacteroides Species during Treatment of C. Difficile Infection". Antimicrobial Agents and Chemotherapy. 53 (1): 261–3. doi:10.1128/AAC.01443-07. PMC 2612159. PMID 18955523.
- ↑ Johnson, Stuart (2009). "Recurrent Clostridium difficile infection: A review of risk factors, treatments, and outcomes". Journal of Infection. 58 (6): 403–10. doi:10.1016/j.jinf.2009.03.010. PMID 19394704.